Press Releases May 1, 2026 08:00 AM

TON Strategy Company Sets First Quarter 2026 Conference Call for Tuesday, May 12, 2026 at 9:00 a.m. ET

TON Strategy Company schedules Q1 2026 earnings conference call for May 12, 2026

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
TONX

TON Strategy Company announces a conference call on May 12, 2026 to discuss its Q1 financial results ending March 31, 2026. The company focuses on accumulating Toncoin ($TON), the native cryptocurrency of Telegram's platform, through various means including capital raising proceeds and staking rewards. It also operates legacy business units related to livestream shopping and AI-powered social commerce.

TON Strategy Company Sets First Quarter 2026 Conference Call for Tuesday, May 12, 2026 at 9:00 a.m. ET
TONX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Conference call set for May 12, 2026 to discuss Q1 2026 financials
  • Company's core business centers on digital asset accumulation of Toncoin ($TON) and staking activity
  • Operates additional business units in livestream shopping and AI-powered social commerce sectors

LAS VEGAS, May 01, 2026 (GLOBE NEWSWIRE) -- TON Strategy Company (Nasdaq: TONX), a digital asset treasury company dedicated to holding Toncoin ($TON), will hold a conference call on Tuesday, May 12, 2026 at 9:00 a.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2026. Financial results will be issued in a press release prior to the call.

TON Strategy management will host the presentation.

Date: Tuesday, May 12, 2026
Time: 9:00 a.m. Eastern time
U.S. dial-in: 1-877-407-0789
International dial-in: 1-201-689-8562
Conference ID: 13760424

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting to the conference call, please contact Gateway Group at 949-574-3860.

The conference call will be broadcast live and available for replay here and via the investor relations section of the Company’s website.

A replay of the call will be available after 12:00 p.m. Eastern time on the same day through May 26, 2026.

Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 13760424

About TON Strategy Company
TON Strategy Company (Nasdaq: TONX) is focused on the accumulation of $TON – the native cryptocurrency of Telegram’s billion-user platform – for long-term investment, whether acquired through deployment of proceeds from capital raising activity, staking rewards or via open market purchases. The Company aims to steadily expand its $TON holdings, stake $TON, and support the development of a tokenized economy inside Telegram.

In addition, the Company continues to operate legacy business units, including MARKET.live, a multi-vendor livestream shopping platform, and LyveCom, an AI-powered social commerce innovator that enables brands and merchants to deliver omnichannel livestream shopping experiences across websites, apps, and social platforms.

Investor Relations and Media Contact:
Gateway Group, Inc.
949-574-3860
TONX@gateway-grp.com


Risks

  • Cryptocurrency markets are volatile leading to potential fluctuations in asset value impacting financial results
  • Dependence on the growth and adoption of Telegram's platform and its tokenized economy
  • Competition and technological challenges in the livestream shopping and social commerce sectors may affect legacy business performance

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026